The insider sales are routine profit-taking following deep-in-the-money option exercises. At 0.015% of market cap, this cluster carries no bearish signal. Monitor for any 10b5-1 plan adoption or further acceleration of sales, but this filing alone does not warrant action.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 15 $204.86entry
- T+1 · 2mo ago −4.36%α −3.92% · $195.92
- T+5 · 8w ago −5.86%α −7.98% · $192.86
- T+20 · 5w ago −8.02%α −10.74% · $188.44
- T+44 · todayOpen
- T+60 · in 22d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Revolution Medicines executed a cluster of open-market sales totaling ~$6.5M over three days, with the bulk from C-suite executive Anthony Mancini ($3.15M) and director Lorence Kim ($3.59M). The sales follow option exercises by Mancini at $33.62/share, locking in massive gains at current ~$205 prices. At a $43.7B market cap, the total represents ~0.015%, well below the 0.1% materiality threshold, making this a routine liquidity event rather than an informed bearish signal. The cluster is amplified by the cross-filing insider-trades context, but the proportionality check overrides: the dollar amount is trivial relative to company size.
Key Financial Metrics
Key Facts
- Anthony Mancini (C-suite) sold 15,448 shares for ~$3.15M on Sep 10 after exercising options at $33.62/share
- Lorence Kim (Director) sold 17,090 shares for ~$3.59M on Sep 8
- Total open-market sales: ~$6.5M, representing ~0.015% of $43.7B market cap
- Mancini also exercised 9,363 shares at $0 (non-cash) on Sep 10
- No open-market purchases in the cluster, net direction is selling
Financial Impact
~$6.5M in insider sales, ~0.015% of market cap, trivial
Risk Factors
- Insider selling could accelerate if the stock continues to rally
- Option exercises followed by sales may signal insiders view current valuation as full
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RVMD-1789425868525 |
Track record
44 reports on RVMD
7 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 17 of 18 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers